Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04642079 · ClinicalTrials.gov registry record · Phase 3
Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 839
- Enrollment target
NCT04642079 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 839 participants.
The verdict
NCT04642079, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 839 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety and immunogenicity of 20vPnC in healthy children 15 months through 17 years of age
Interventions
- BIOLOGICAL 20vPnC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 839 participants |
| Start Date | 2020-12-04 |
| Est. Completion | 2022-04-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04642079
The ClinicalTrials.gov registry entry for NCT04642079 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 839 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 20vPnC is the first listed.
NCT04642079 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04642079 about?
NCT04642079 is a clinical study titled "Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age". This study is designed to evaluate the safety and immunogenicity of 20vPnC in healthy children 15 months through 17 years of age
What is the current status of trial NCT04642079?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 839 participants. The study started on 2020-12-04. Estimated completion is 2022-04-06.
What interventions are being tested in trial NCT04642079?
The interventions under investigation include: 20vPnC (BIOLOGICAL).
Who is sponsoring clinical trial NCT04642079?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.